ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.

Bone Marrow Transplant · 2024 · PMC10920188 · PMID 38184740

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In the same manuscript, a highly significant increase in non-relapse mortality (NRM) of alloSCT recipients with cGVHD vs. control alloSCT recipients was described.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.